



REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	Application No.: 10/024,858 Filing Date: December 18, 2001 First Named Inventor: Graham Leonard Group Art Unit: 1615 Examiner: H. Sheikh Attorney Docket No.: P31220X2C2R5
CERTIFICATION OF FACSIMILE TRANSMISSION I hereby certify that this paper is being facsimile transmitted to the FAX RECEIVED U.S. Patent and Trademark Office on the date shown below. <div style="text-align: center;"> Theresa M. Munro Type Name of Person faxing this document  Signature </div> <div style="text-align: right;"> OCT 05 2006 OFFICE OF PETITIONS Date </div>	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1. **Submission required under 37 C.F.R. § 1.114**
 - a. ☐ Previously submitted
 - i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered)
 - ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - iii. ☐ Other _____
 - b. ☒ **Enclosed**
 - i. ☐ Amendment/Reply _ pages
 - ii. ☐ Affidavit(s)/Declaration(s) _____ pages
 - iii. ☒ Information Disclosure Statement (IDS) 1 page
 - iv. ☒ Form PTO 1449 1 pg. & 2 References
 - v. ☐ Return Receipt Postcard (MPEP 503) (specifically itemized)
 - vi. ☒ Other: Petition for Withdraw of Patent from issue (2 pages).
2. **Miscellaneous**
 - a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(I) required)
 - b. ☐ Other _____
3. **FEES** The RCE fee under 37 C.F.R. § 1.117(c) is required by 37 C.F.R. § 1.114 when the RCE is filed.
 - a. ☒ The Director is hereby authorized to charge the following fees or credit any overpayments, to **Deposit Account No. 19-2570.**
 - ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))
 - i. ☒ RCE fee required under 37 C.F.R. § 1.17(e). \$790.00
 - ii. ☐ () Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
 - iii. ☐ Additional Fees
 - iv. ☒ **Total Fee to be charged to Deposit Account 19-2570** **\$790.00**

CORRESPONDENCE ADDRESS Address GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Telephone (610) 270-5023 Facsimile (610) 270-5090	RESPECTFULLY SUBMITTED, Signature  NAME Wayne J. Dushman Registration No. 33,870
--	--

n:\wjd\paroxetine\P312220 Paxil CR\RCE-5.doc

10/06/2006 CKHLOK 00000011 192570 10024858

FC: 180V \$790.00 OP